Facebook Twitter Linkedin NASDAQ Market NewsClick here to email authorNEXT STORYTurning Point Therapeutics Announces Program Updates and Milestones for 2020PREV STORYDelcath Completes Enrollment in its United States Registration Pivotal Trial (FOCUS) Investigating Melphalan/HDS in the Treatment of Patients with Unresectable Hepatic-Dominant Ocular Melanoma